WANA (Oct 25) – Iranian specialists at a knowledge-based company affiliated with Royan Scientific Center have successfully produced a vital component of the umbilical cord stem cell process entirely within Iran, marking a significant step in the country’s biotechnology sector.

 

In recent years, umbilical cord blood transplants and stem cells extracted from them have been used as definitive treatments for certain blood disorders and blood cancers. Beyond oncology, this technology also plays a critical role in treating genetic disorders, cardiovascular diseases, and immune system deficiencies.

 

A key product in this process is the polymer serum for stem cell separation — an advanced solution that enables precise separation of stem cells from cord blood, while enhancing their differentiation capacity and longevity, thereby improving treatment effectiveness.

 

Previously, this product was entirely imported from European countries, but after several years of dedicated work by specialized teams, its domestic production has now been achieved at the request of the Umbilical Cord Blood Storage Center.

 

Experts note that the new Iranian product costs only one-third of its foreign equivalent and has the potential to transform stem cell-based therapies. Umbilical cord stem cells, besides their ability to differentiate into various cell types, can regenerate damaged tissues and have shown definitive results in the treatment of thalassemia, cancers, and immune deficiencies.

 

Project implementers added that the number of companies producing this product for specialized umbilical cord stem cell separation has now reached 10 domestic entities, and the commercialization and domestic supply process has been fully launched.

Iran Produces Domestic Cord Stem Cell Polymer Serum. Social media/ WANA News Agency

Iran Produces Domestic Cord Stem Cell Polymer Serum. Social media/ WANA News Agency